Abstract:The rational selection of hepatitis C virus (HCV) vaccine antigen will aid in the prevention of future chronic liver disease burden and associated healthcare costs. We have previously shown that HCV E2 glycoprotein is not highly immunogenic, and the modification of E2 reduced CD81 binding and displayed altered cytokine and protective immune responses in vitro and in a surrogate mouse model. Here, we compared the influence of a parental and a modified sE2F442NYT glycoprotein region from HCV genotype 1a for the activation of peripheral blood mononuclear cell (PBMC)-derived dendritic cells (DCs), CD4+T cells, and B cells. Modified sE2F442NYT, when incubated with DCs, induced a higher number of CD86-positive cells. The sE2F442NYT or parental sE2 encapsulated as mRNA-lipid nanoparticle (sE2F442NYT mRNA-LNP) primed DCs co-cultured with autologous CD4+T cells did not induce CD25 or forkhead box P3 expression. PBMC-derived CD4+T cells treated with sE2F442NYT exhibited enhanced signal transducer and activator of transcription (Stat)1/Stat4 phosphorylation in response to anti-CD3/CD28 stimulation in comparison to parental sE2 treatment and facilitated isotype switching in B cells, leading to the generation of a broader subclass of antibodies. Cells treated with modified sE2F442NYT displayed an increase in activated Stat3 and extracellular signal-regulated kinase (ERK). Likewise, PBMC-derived naïve B cells upon in vitro stimulation with sE2F442NYT induced an increased proliferation, Stat3 and ERK activation, and protein kinase B (Akt) suppression. Thus, the modified sE2F442NYT antigen from HCV facilitates improved DC, CD4+T, and B cell activation compared to parental sE2 to better induce a robust protective immune response, supporting its selection as an HCV candidate vaccine antigen for preclinical and clinical HCV vaccine trials.IMPORTANCEThe nature of an enhanced immune response induced by sE2F442NYT will help in the selection of a broad cross-protective antigen from hepatitis C virus genotypes, and the inclusion of relatively conserved sE1 with sE2F442NYT may further strengthen the efficacy of the candidate vaccine in evaluating it for human use.

Cellular Immunogenicity of a Multi-Epitope Peptide Vaccine Candidate Based on Hepatitis C Virus NS5A, NS4B and Core Proteins in HHD-2 Mice.

Scan-Time Reduction Using Noise-Matched Images in 2- and 3-Dimensional Bismuth Germanate PET/CT: Clinical Study in Head and Neck Cancer

Specific immune responses induced by a multi-epitope antigen of hepatitis C virus in mice and rabbits

Hepatitis C Virus E2 Protein Encapsulation into Poly D, L-Lactic-co-glycolide Microspheres Could Induce Mice Cytotoxic T-cell Response.

Minicircle-based vaccine induces potent T-cell and antibody responses against hepatitis C virus

Bioinformatics analysis of multi-epitope peptide vaccines against Hepatitis C virus: a molecular docking study

A Candidate DNA Vaccine Elicits HCV Specific Humoral and Cellular Immune Responses.

Immunogenicity study of a Novel DNA-Based HCV vaccine candidate

Multi-epitope vaccine design for hepatitis E virus based on protein ORF2 and ORF3

The structural HCV genes delivered by MPG cell penetrating peptide are directed to enhance immune responses in mice model

Hepatitis C virus modified sE2F442NYT as an antigen in candidate vaccine facilitates human immune cell activation

Reply to Tan et al.

Design Technique for Enhancing Software Quality and Development Suitability

Reverse vaccinology approach for identification of epitopes from E1 protein as peptide vaccine against HCV: A proof of concept

A Novel Adeno-Associated Virus-Based Genetic Vaccine Encoding The Hepatitis C Virus Ns3/4 Protein Exhibits Immunogenic Properties In Mice Superior To Those Of An Ns3-Protein-Based Vaccine

Broadband high-gain Linearly Tapered Slot Antenna with outside corrugations

DCs Pulsed with Novel HLA-A2-restricted CTL Epitopes Against Hepatitis C Virus Induced a Broadly Reactive Anti-Hcv-specific T Lymphocyte Response.

Protective CD8+ T-cell response against Hantaan virus infection induced by immunization with designed linear multi-epitope peptides in HLA-A2.1/Kb transgenic mice

[Blastocystis hominis: epidemiological and clinical remarks from more than 3,500 stool examinations].

Hepatitis B virus core particles containing multiple epitopes confer protection against enterovirus 71 and coxsackievirus A16 infection in mice

Design of a novel multi-epitope vaccine candidate against hepatitis C virus using structural and nonstructural proteins: An immunoinformatics approach